Case Studies

Challenge Our client was a leading UK Research Institute requiring assistance in assigning internal commercialization funding to the most promising research groups within the University. Alacrita was...

Challenge A leading UK University was developing an innovative technology to permit the creation of surface-immobilized functional RNAs in a microarray format, by transcription and ‘printing’ from...

Challenge A leading UK University was developing a ‘3-in-1’ PCR-based assay for rapid cell line verification and purity testing. The technology comprised a PCR-based assay containing novel markers...

Challenge: Alacrita provided interim chief medical officer support to an oncology company over the course of two years. The company was a developing a portfolio of first in class small molecules to...

Challenge A research-based biotech needed a clear understanding of the processes, resources and timelines to establish a global pharma supply chain for their leading pipeline compound, a therapy for...

Challenge A small biotech company was developing a peptide and needed support in taking the compound to first-in-man studies and Phase II clinical trials. This was the first time the company had...

Challenge A biotech company was developing its first oral compound — a novel small molecule. The company needed support in taking the compound to first-in-man studies and Phase II clinical trials.

Challenge A US venture-funded biotech was planning a pivotal trial with a highly efficacious infectious disease therapy. It asked Alacrita’s pharma market access consultants to conduct a high-level...

Challenge: Our client needed an assessment of the market opportunity and value proposition for a novel anemia therapy in order to facilitate discussions with potential partners.

Challenge An established US biotech, aware of the importance of incorporating market access factors into clinical trial design, wanted to conduct strategic research for a novel advanced breast cancer...

Challenge A UK company had developed a novel system for urinary drainage that provided a number of benefits for patients and caregivers over current systems. It believed that CE marking would be...

Challenge A licensor of a marketed oncology drug needed support with monetizing its royalty stream. Alacrita was engaged to develop an independent market-based valuation of the product.